Stoke Therapeutics (STOK) Deferred Taxes (2018 - 2019)
Stoke Therapeutics (STOK) posted quarterly Deferred Taxes of $6000.0 for Q4 2019, up 185.71% year-over-year from $2100.0 in Q4 2018, and down 25.0% quarter-over-quarter from $8000.0 in Q3 2019.
Powered by 
Analysis
Stoke Therapeutics (STOK) Deferred Taxes (2018 - 2019) Analysis & Trends
Stoke Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $6000.0 for Q4 2019.
- In Q4 2019, Deferred Taxes rose 185.71% year-over-year to $6000.0; the TTM figure through Dec 2019 stood at $28000.0 (changed N/A YoY), while the FY2019 annual figure was $28000.0, up 380.0% from the prior year.
- Deferred Taxes for Q4 2019 stood at $6000.0, down from $8000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $8000.0 in Q3 2019, with the low at -$7000.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 6,000.00 |
| Sep 30, 2019 | 8,000.00 |
| Jun 30, 2019 | 7,000.00 |
| Mar 31, 2019 | 7,000.00 |
| Dec 31, 2018 | -7,000.00 |
| Sep 30, 2018 | -1,000.00 |